Brawn Biotech Q1 FY27 results, new auditor recommended for 5-year term

Results View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.0%Reaction day

₹20.30

prior close

—

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-0.2% vs market

Pharmaceuticals peers, median of 166sector+0.1%-0.2% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.0+0.2-0.2+0.1-0.2

Next day

-0.0+0.2-0.3-0.3+0.2

+4.9+0.4+4.6-0.2+5.1

+10.0+0.7+9.3-0.4+10.5

+9.4+0.1+9.2-1.5+10.8

+8.8+0.7+8.1-0.9+9.7

+14.2+1.2+13.0-0.6+14.8

15d

+11.3+0.7+10.6+0.3+11.0

+13.3-1.2+14.5-0.2+13.5

+14.8-1.1+15.9-2.4+17.2

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Brawn Biotech board approved unaudited Q1 FY27 results (quarter ended June 30, 2026) and recommended appointing M/s G D S M and Co as new statutory auditors for a 5-year term starting from the 41st AGM. The 41st AGM is scheduled for September 29, 2026 via video conferencing. Limited review by current auditor Rajiv Udai and Associates found no material misstatements. Key quarterly financials were disclosed in the prescribed format with no qualifications, and the CFO certified the results.

Likely market impact

Routine quarterly filing. Auditor change from Rajiv Udai and Associates to GDSM and Co for next 5 years is a governance point worth noting for shareholders.